CONGENITAL HYPOTHYROIDISM: AWARENESS, DIAGNOSIS AND TREATMENT IN PAEDIATRICS
People In Health Care
Associate Professor Michelle Jack, Paediatric Endocrinologist
Clinical Practice & Co-Lead Doctor of Medicine, Bond University, Queensland
Filmed Robina, Queensland | October 2024
Michelle Jack is Associate Professor of Clinical Practice, Faculty of Health Sciences & Medicine at Bond University, QLD, co-Head of Paediatrics and a Paediatric Endocrinologist at Lismore Base Hospital in NSW and Senior Staff Specialist, Paediatric Endocrinology, Northern New South Wales Local Health District.
Associate Professor Jack is a member of the ANZSPED Laboratory and Newborn Screening Sub-committee https://anzsped.org/subcommittees/lab-group/ and Thyroid working group https://anzsped.org/subcommittees/thyroid-working-group/.
Australian Health Journal spoke to Associate Professor Jack about congenital hypothyroidism and newborn screening and her concerns in the varying thresholds for across different states in Australia. Despite the existence of newborn screening programs since the 1970s, there is still controversy surrounding the appropriate screening levels. Congenital hypothyroidism, affecting about one in 3500 infants, can lead to severe intellectual and physical impairment if not diagnosed early. The condition is mainly caused by the thyroid gland’s failure to develop properly, resulting in insufficient thyroid hormone production.
The current challenge lies in setting the right screening thresholds to avoid false positive or missed diagnoses. Assoc Prof Jack highlights the need for standardisation in the approach to borderline thyroid abnormalities in children, as the wide variety of responses from paediatric endocrinologists indicates a lack of consensus. She emphasises the importance of conducting high-quality research to determine the optimal screening thresholds, considering both the impact on infants and their families and the healthcare system’s cost.
Associate Professor Jack is passionate about the health and wellbeing of children and adolescents, with diverse research areas including the impacts of family friendly workplace initiatives, screening and management of thyroid disorders in infants and children. She supports her First Nations colleagues on Indigenous-led research projects funded by the Medical Research Future Fund, aiming to improve the social and emotional wellbeing of First Nations Children. Through her clinical and academic roles, Michelle hopes to make a positive difference to the health and well-being of children and their families.
References on congenital hypothyroidism
ANZSPED website resources on congenital hypothyroidism
– https://anzsped.org/patient-resources/hormones-me-booklet-series/
– https://anzsped.org/patient-resources/anzsped-patient-flyers/)
Fifty years of newborn screening for congenital hypothyroidism: current status in Australasia and the case for harmonisation
-
WA and QLD RSV Immunisation programs show drops in infant hospitalisations
RSV is the number one cause of hospitalisation of Australian children under five years of age, according to the Immunisation Foundation of Australia (IFA). There are mounting concerns that Australians at greatest risk of severe Respiratory Syncytial Virus, or RSV will miss out on protection against the lung infection, with the Federal Government failing to commit to a national RSV immunisation program.
-
Detection and prevention of Alzheimer’s Disease and Related Dementias
Professor Vicky Vass serves as the Chief Executive Officer of Alzheimer’s Research Australia, which is based in Perth, Western Australia. Australian Health Journal met with Professor Vass to hear of the organisation’s mission to solve the mysteries surrounding Alzheimer’s disease, and focus on detection as the key to their efforts.
-
Mission to raise awareness of sarcoma and need for clinical trial funding
Sarcoma, a rare and aggressive cancer, remains the deadliest cancer for children and young adults, accounting for nearly one third (30%) of cancer-related deaths among those aged 15–24 and one tenth (10%) of those aged 0–14. Further, still severely under-diagnosed, sarcoma only accounts for one sixth (15%) of all cancer diagnoses in the 15 – 24 age group, and less than a tenth (8%) among children under 10.
